REMARKS

In response to the Office communication mailed on March 29, 2001, and to the accompanying Notice to Comply with Requirements for Patent Application Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, and in accordance with 37 C.F.R. §1.821 (c) and (e), a Sequence Listing in paper form and a copy of the Sequence Listing in computer readable form are submitted herewith.

Applicants respectfully submit that the contents of the paper version of the Sequence Listing and the computer readable version of the Sequence Listing are the same and do not add new matter.

The amendments to the specification referred to above are made to insert SEQ ID NOs as appropriate. The inserted text is underlined and bolded for the Examiner's convenience. Consideration and entry of these amendments before examination of the application is respectfully requested.

If there are any questions concerning this amendment or the attached Sequence Listing, please contact Applicants' primary representative, Ann Mueting, at (612) 305-1217.

CERTIFICATE UNDER 37 C.F.R. 1.8:
The undersigned hereby certifies that this paper is being deposited in the United States Postal Service, as first class mail, in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on this 30th day of April, 2001.

David L. Provence

Date
DLP/mi

Respectfully submitted,
G. FIELDS, ET AL.
By Applicants' Representatives,
Mueting, Raasch & Gebhardt, P.A.
P.O. Box 581415
Minneapolis, MN 55458-1415
Phone: (612) 305-1220
Facsimile: (612) 305-1228

By: David L. Provence

David L. Provence
Reg. No. 43,022
Direct Dial (612) 305-1005

APPENDIX A
SPECIFICATION AMENDMENTS
INCLUDING NOTATIONS TO INDICATE CHANGES MADE

Applicant(s): G. Fields, et al.
Serial No. 09/529,691
Filed 29 August 2000
INHIBITION OF TUMOR CELL ADHESION TO TYPE IV COLLAGEN
Attorney Docket No. 110.00680101

In the Specification

The paragraph beginning at page 3, line 5, has been amended as follows:

Schnolzer and Kent (M. Schnolzer et al., *Science*, *256*, 221-225 (1992)) synthesized all-L and all-D HIV-1 proteases, then examined the chiral specificity of the two enzymes using the substrate 2-aminobenzoyl-Thr-Ile-Nle-Nph-Gln-Arg-NH_2 (where Nph is nitrophenylalanine) **(SEQ ID NO:2)**. The synthetic all-L enzyme cleaved only the all-L, not the all-D, version of 2-aminobenzoyl-Thr-Ile-Nle-Nph-Gln-Arg-NH_2 **(SEQ ID NO:2)** while the synthetic all-D enzyme cleaved only the all-D substrate. The chiral specificity of enzymes was established by these results.

The paragraph beginning at page 3, line 28, has been amended as follows:

In one embodiment, the formula of the polypeptide is: gly-val-lys-gly-asp-lys-gly-asn-pro-gly-trp-pro-gly-ala-pro **(all-L form: SEQ ID NO:1)**. This specific polypeptide formally substantially corresponds to isolated type IV collagen residues 1263-1277 from the major triple helical region of the α1 chain of type IV collagen, although all the amino acids are in the D-form where appropriate (gly is in neither the L nor the D form). The single letter amino acid code for this polypeptide is GVKGDKGNPGWPGAP. Herein, this specific polypeptide is designated "D-IVH1".